89bio Q2 net loss $48M; appoints ex-CymaBay CSO Charles McWherter to board; Phase 3 MASH trials enrolling

89bio, Inc.

2024-Q2 EPS reported -$1.02

Net loss $48.0M for Q2 2024 vs $38.4M YoY; R&D expenses rose to $44.9M.
Cash, equivalents and marketable securities $531.4M as of June 30, 2024.
Phase 3 ENLIGHTEN-Fibrosis (F2-F3 MASH) and ENLIGHTEN-Cirrhosis (F4) enrolling patients.
Phase 3 ENTRUST (SHTG) topline data expected in 2025; enrollment ongoing.
Charles McWherter, Ph.D., former CSO/President R&D of CymaBay (acquired by Gilead), appointed to Board of Directors.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles McWherter

member of the Board

89bio, Inc.

Effective: 2024-07-30
Filed: August 5, 2024, 7:59 PM ET

On July 30, 2024, the board of directors (the “Board”) of the Company appointed Charles McWherter, Ph.D. as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles McWherter was appointed as member of the Board at 89bio, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

On July 30, 2024, the board of directors (the “Board”) of the Company appointed Charles McWherter, Ph.D. as a member of the Board.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-193906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.